Until now there hasn’t been a selective therapeutic agent to exploit this observation and so I am extremely excited to see Circle Pharma’s cyclin A/B RxL inhibitor move into the clinic." ...

This seems to be the case with Dan Sundheim of D1 Capital Partners. The once high-flying Tiger Grandcub lost 31 percent in January 2021 when it became a victim of the meme stock attack by rogue ...